M&A/Shareholder vote/2026/Personalis, Inc.

Personalis, Inc. PSNL

Tempus AI, Inc. is buying Personalis, Inc. (PSNL), paying holders in stock. develops, markets, and sells advanced cancer genomic testing services used by physicians and pharmaceutical companies.

Holders get
Stock
0.3356 shares of Tempus Class A Common Stock if Tempus Stock Price ≤ $48.42, or $16.25 divided by Tempus Stock Price if Tempus Stock Price > $48.42, with potential for up to 50% to be paid as $16.25 in cash per share
Deal value
Not given
Expected close
Not given
Status
Pending
Checked
See the filing →

Filed

The deal

Tempus AI, Inc. is acquiring Personalis, Inc. (PSNL), which develops, markets, and sells advanced cancer genomic testing services used by physicians and pharmaceutical companies. Each holder receives 0.3356 shares of Tempus Class A Common Stock if Tempus Stock Price ≤ $48.42, or $16.25 divided by Tempus Stock Price if Tempus Stock Price > $48.42, with potential for up to 50% to be paid as $16.25 in cash per share.

The deal requires HSR Act waiting period expiry or termination, approval of holders of majority of outstanding Personalis Common Stock, absence of material legal restraints, and accuracy of representations and warranties. The vote is scheduled for November 30, 2026, and the expected close is not stated.

What has happened

Agreement signed · See the filing
Regulators cleared the deal · The HSR Act waiting period applicable to the Mergers expired at 11:59 p.m., Eastern time, on October 2, 2026. · See the filing
Holders sent the terms and a meeting date

What must happen first

HSR Act waiting period expiry or termination
approval of holders of majority of outstanding Personalis Common Stock
absence of material legal restraints
accuracy of representations and warranties

The board says

The Personalis Board unanimously recommends FOR the Merger Proposal.